What is Ondero Tablet used for?

Ondero 5 mg Tablet 10’s is primarily used to treat Type 2 diabetes mellitus. It contains Linagliptin, which belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors used Ondero 5 mg Tablet 10’s is prescribed for type 2 diabetes when diet and exercise alone cannot control their blood sugar levels.

When should Ondero be taken?

Ondero 5mg Tablet can be taken with or without food at any time of the day. If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.

What is linagliptin tablets used for?

Linagliptin: medicine to treat type 2 diabetes – NHS.

What is linagliptin 5 mg used for?

Linagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally).

Is Ondero 5mg a steroid?

Ondero 5 mg Tablet is an antidiabetic medicine used alone or in combination with other medicines to treat type 2 diabetes in adults. It works by increasing the activity of hormones (chemical messengers) that help to lower the sugar levels in your blood.

What is the brand name for linagliptin?

Tradjenta (linagliptin) is an add-on medication to diet and exercise to improve blood sugar control in people with type 2 diabetes.

When is it best to take linagliptin?

You can generally take the tablet at a time of day to suit you, but it is best to take your doses at the same time of day each day. You can take these tablets either with or without food.

Is linagliptin an insulin?

It has been shown that linagliptin is an effective and safe add-on therapy to insulin in patients with T2DM. The efficacy and safety of this combination was also shown in vulnerable, elderly T2DM patients and in patients with T2DM and renal impairment.

Can linagliptin cause heart failure?

In patients with type 2 diabetes mellitus and concomitant atherosclerotic vascular disease and/or diabetic kidney disease, the antihyperglycemic medication linagliptin did not affect risk for heart failure hospitalization or other associated heart failure–related complications.

Does linagliptin cause weight loss?

Linagliptin administered perorally (1.5mg/kg, b.i.d.), but not subcutaneously (0.5mg/kg, b.i.d.), evoked a very modest body weight loss (2.2%) after 28 days of treatment. GLP-1 (0.5mg/kg, s.c.) treatment alone induced a body weight loss of 4.1%.

What is the best time to take linagliptin?

When is the best time to take linagliptin?